Molecular Diagnostics for Transplant Market Research Report Forecast till 2030
Market Overview
Molecular Diagnostics for Transplant Market is anticipated to register a CAGR of 8.91% during the review period.
Expanding pervasiveness of irresistible illnesses, rising number of transplant systems, and progressions in molecular symptomatic methods are reinforcing the market development.
There has been a rising pervasiveness of irresistible illnesses attributable to different factors, for example, environmental change, quick urbanization, microbial development, among others. Exceptional consideration should be accepted before transplantation as a transplant patient can get any kind of contamination brought about by microorganisms, infections, organisms and parasites. These incorporate flu infection contamination, urinary lot disease, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr infection, Human herpesvirus 6, among a few others. Besides, expanding antimicrobial obstruction is likewise a reason for serious concern and has been adding to the rising predominance of irresistible infection. For example, as per the Communities for Infectious prevention and Anticipation, more than 2.8 million antimicrobial-safe contaminations happen in the US every year. Subsequently, expanding commonness of irresistible sickness has driven the interest for execution of exhaustive molecular diagnostics in transplantation, in this manner, driving the market.
Market Segmentation
The Molecular Diagnostics for Transplant Market, based on product is segmented into reagents & kits, instruments, and services & software.
Based on technology the market is divided into polymerase chain reaction (PCR), sequencing, microarray, and others.
Based on end user, the market has been classified into the hospitals and transplant centers, research laboratories & academic institutes, and others.
Regional Insights
North America molecular diagnostics for transplant market represented the biggest piece of the pie in 2021, because of rising interest innovation development and expanding rates of ongoing sicknesses that lead to an expansion in organ transplants. As per research, the quantity of kidneys, liver, heart, lung, pancreas, and digestive tract transplants is expanding in the US, while the quantity of kidney transplants is expanding in Canada.
Europe molecular diagnostics for transplant market represents the second-biggest market attributable to the rising pervasiveness of constant infections, including kidney, cardiovascular sicknesses (CVD), and respiratory illnesses. Headways in molecular diagnostics have worked on the recognizable proof and comprehension of explicit quality imperfections for the suitable organ transplant in kidney, heart, and lung disappointment. CVD illnesses are impacted by variables, for example, atherosclerosis, blood clusters, diabetes, a stationary way of life, and weight, which might prompt heart disappointment.
The Asia-Pacific molecular diagnostics for transplant market is supposed to develop at a critical share from 2022 to 2030. The region's developing geriatric populace requests organ transplantation, which might change according to organ disappointment. In 2020, as per the World Financial Forum, China, India, and Japan had the most established populaces universally. Moreover, it has been assessed that by 2050, one of every four matured individuals will be living in the region.
Major Players
Key Companies in the Molecular Diagnostics for Transplant Market are Thermo Fisher Scientific Inc. (US), Abbott Laboratories, Inc. (US), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), BioMérieux SA (France), Hoffmann-La Roche Ltd. (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), and Others.
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030(USD MILLION)
TABLE 3 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR REAGENTS & KITS, BY REGION, 2018–2030(USD MILLION)
TABLE 4 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR INSTRUMENTS, BY REGION, 2018–2030(USD MILLION)
TABLE 5 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR SERVICES & SOFTWARE, BY REGION, 2018–2030(USD MILLION)
TABLE 6 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030(USD MILLION)
TABLE 7 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018–2030(USD MILLION)
TABLE 8 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR SEQUENCING, BY REGION, 2018–2030(USD MILLION)
TABLE 9 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR MICROARRAY, BY REGION, 2018–2030(USD MILLION)
TABLE 10 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR OTHERS, BY REGION, 2018–2030(USD MILLION)
TABLE 11 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030(USD MILLION)
TABLE 12 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2018–2030(USD MILLION)
TABLE 13 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018–2030(USD MILLION)
TABLE 14 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR OTHERS, BY REGION, 2018–2030(USD MILLION)
TABLE 15 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION, 2018–2030 (USD MILLION)
TABLE 16 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 17 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 18 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 19 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 20 US MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 21 US MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 22 US: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 23 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 24 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 25 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 26 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 27 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 28 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 29 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 30 GERMANY MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 31 GERMANY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 32 GERMANY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 33 UK MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 34 UK: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 35 UK: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 36 FRANCE MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 37 FRANCE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 38 FRANCE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 39 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 40 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 41 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 42 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 43 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 44 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 45 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 46 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 47 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 48 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 49 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 50 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 51 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 52 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 53 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 54 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 55 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 56 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 57 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 58 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 59 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 60 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 61 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 62 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 63 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 64 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 65 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 66 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 67 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 68 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 69 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 70 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 71 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 72 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 73 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 74 MIDDLE EAST MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 75 MIDDLE EAST: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 76 MIDDLE EAST: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 77 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 78 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 79 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 80 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
TABLE 81 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 82 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 83 MAJOR PLAYERS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
TABLE 84 MOST ACTIVE PLAYER IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
TABLE 85 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 86 PARTNERSHIP/AGREEMENT
TABLE 87 MERGER/ACQUISTION
TABLE 88 BIOMÉRIEUX SA: PRODUCT OFFERED
TABLE 89 BIOMÉRIEUX SA: KEY DEVELOPMENTS
TABLE 90 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE OFFERED
TABLE 91 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
TABLE 92 CEPHEID: PRODUCT/SERVICE OFFERED
TABLE 93 CEPHEID: KEY DEVELOPMENTS
TABLE 94 ALTONA DIAGNOSTICS GMBH: PRODUCTS OFFERED
TABLE 95 ALTONA DIAGNOSTICS GMBH: KEY DEVELOPMENTS
TABLE 96 ELITECHGROUP: PRODUCTS OFFERED
TABLE 97 ELITECHGROUP: KEY DEVELOPMENTS
TABLE 98 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 99 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS
TABLE 100 HOLOGIC, INC: PRODUCTS OFFERED
TABLE 101 HOLOGIC INC.: KEY DEVELOPMENTS
TABLE 102 QIAGEN N.V.: PRODUCTS OFFERED
TABLE 103 QIAGEN N.V.: KEY DEVELOPMENTS
TABLE 104 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
TABLE 105 BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS
TABLE 106 ABBOTT: PRODUCTS OFFERED
TABLE 107 ABBOTT: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET STRUCTURE
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 3 MARKET DYNAMICS: GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
FIGURE 4 DRIVER IMPACT ANALYSIS
FIGURE 5 RESTRAINT IMPACT ANALYSIS
FIGURE 6 VALUE CHAIN ANALYSIS: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
FIGURE 8 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY PRODUCT 2021
FIGURE 9 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2021 & 2030 (USD MILLION)
FIGURE 10 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2021 & 2030 (USD MILLION)
FIGURE 11 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2021 & 2030 (USD MILLION)
FIGURE 12 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION 2021 & 2030 (USD MILLION)
FIGURE 13 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY REGION, 2021
FIGURE 14 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021
FIGURE 15 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021
FIGURE 16 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021
FIGURE 17 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021
FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
FIGURE 20 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET: COMPETITIVE LANDSCAPE
FIGURE 21 SALES 2021
FIGURE 22 R&D EXPENDITURE, 2021
FIGURE 23 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 BIOMÉRIEUX SA: SWOT ANALYSIS
FIGURE 25 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
FIGURE 27 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS
FIGURE 29 HOLOGIC INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 QIAGEN N.V.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 QIAGEN N.V.: SWOT ANALYSIS
FIGURE 32 BECTON, DICKINSON AND COMPANY : FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS
FIGURE 34 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們